Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 1.25B 1.1B 1.02B 939M 1.76B 121B 1.79B 12.15B 4.75B 59.3B 4.7B 4.6B 205B P/E 2026 *
-8.3x
P/E 2027 * -7.52x
Enterprise Value 1.14B 1B 934M 857M 1.61B 110B 1.63B 11.09B 4.33B 54.13B 4.29B 4.2B 187B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.15%
Yield 2026 *
-
Yield 2027 * -
1 week+13.94%
Current month+13.38%
1 month+29.42%
3 months+22.87%
6 months+5.79%
Current year+54.86%
1 week 9
Extreme 9.002
10.9
1 month 8.15
Extreme 8.146
10.9
3 years 3.7
Extreme 3.7
14.9
5 years 2.2
Extreme 2.2
21.2
Manager TitleAgeSince
Chief Executive Officer 47 07/05/2018
Director of Finance/CFO 52 01/09/2019
Chief Tech/Sci/R&D Officer - 18/08/2025
Director TitleAgeSince
Chairman 68 07/03/2018
Director/Board Member 47 07/05/2018
Director/Board Member 62 01/02/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.71%+13.94%+7.39%+34.40% 1.25B
-1.82%+4.80%+54.32%+68.36% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-0.43%-0.64%+4.50%+421.23% 23.18B
+2.59%-0.73%-18.88%-12.87% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+3.30%+27.41%-29.07% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+1.45%+0.95%+26.28%+185.99% 13.92B
Average +0.78%+1.62%+38.77%+163.80% 26.68B
Weighted average by Cap. +0.11%+1.93%+39.80%+138.46%

Financials

2026 *2027 *
Net sales - -
Net income -156M -137M -128M -117M -220M -15.05B -223M -1.52B -592M -7.4B -587M -574M -25.58B -190M -167M -155M -142M -267M -18.26B -271M -1.84B -719M -8.98B -712M -697M -31.04B
Net Debt -109M -96.02M -89.3M -81.94M -154M -10.53B -156M -1.06B -414M -5.18B -410M -402M -17.9B -231M -203M -189M -173M -326M -22.28B -331M -2.24B -877M -10.95B -868M -850M -37.87B
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
-
Date Price Change
28/07/26 EUR 10.65 -0.37%
24/07/26 EUR 10.69 +11.53%
23/07/26 EUR 9.580 +2.09%
22/07/26 EUR 9.384 -0.72%
21/07/26 EUR 9.452 +3.57%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
12.10USD
Average target price
20.69USD
Spread / Average Target
+71.01%

Quarterly revenue - Rate of surprise